Roland Walter, MD, PhD Allogeneic stem cell transplant (ASCT) is an important treatment for relapsed or refractory acute myeloid leukemia (AML). Reviewing the current research, experts are questioning the benefit of giving therapy before or after patients undergo ASCT. During a debate held at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO […]
Anemia is a common issue in patients with myelofibrosis. © relif – stock.adobe.com Anemia is a common and potentially dangerous condition that can occur in patients with myelofibrosis, a type of myeloproliferative neoplasm. While anemia is a blanket term that describes low hemoglobin levels, myelofibrosis-related anemia behaves quite differently than anemia in patients with a […]
Transcript: Sameh R. Gaballa, MD: This is an area where there’s a lot of heterogeneity in terms of practice. What do you do after you’re done with induction? You get an end-of-treatment PET and the patient is in CR [complete response]. How do you monitor these patients? How often do you get imaging? I agree […]
Introduction In the context of an alarming decline in HPV vaccination coverage globally, from 25% to 15% between 2019 and 2021, the WHO recommends that countries reinforce their HPV vaccination programs.1 Also, according to The European Cancer Organization report, it is estimated that about 29% of girls and 5% of boys were completely vaccinated with […]
Next Article Key Points “Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient resource. “Medical Journeys” chart a path each step of the […]
Abstract Clonal hematopoiesis (CH)—age-related expansion of mutated hematopoietic clones—can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data […]
Rami Komrokji, MD Vice chair, Malignant Hematology Department Head of the Leukemia and MDS Section Moffitt Cancer Center Tampa, FL KOMROKJI: MF could be either primary de novo or coming from secondary from essential thrombocythemia [ET] or polycythemia vera [PT]. [Concerning] the major criteria listed [by the World Health Organization (WHO)], I always bring up […]
Marisol Miranda-Galvis, DDS, MS, PhD Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status. Key takeaways […]
Blood cells © Катерина Євтехова – stock.adobe.com In hematologic cancers, not having health insurance, being treated at a non-academic facility, having a low income or education level, and being unmarried, contribute to inequities in the outcomes for patients, according to findings from a systematic review. Key takeaways from the review were presented at the 2023 […]
Bayside, NY September 07, 2023 –(PR.com)– New York Cancer & Blood Specialists (NYCBS), one of the nation’s leading oncology practices, is proud to announce the addition of oncologist-hematologist Jean Bustamante-Alvarez, MD, MS. Dr. Bustamante-Alvarez will be joining the team in the Upper East Side at 215 E. 95th St., New York, NY 10128. “We are […]